Relay Therapeutics, Inc. (RLAY) has 16 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 15 sales totalling $125.8M. Most recent filing: Sept. 9, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 9, 2026 filed Sept. 8, 2026 | Bergstrom Donald A President, R&D | −$161,814 | 8,530 | −2% | Yes | |
|
|
||||||
| Sept. 9, 2026 filed Sept. 8, 2026 | Catinazzo Thomas Chief Financial Officer | −$335,560 | 17,717 | −13% | Yes | |
|
|
||||||
| Sept. 9, 2026 filed Sept. 8, 2026 | Patel Sanjiv President and CEO | −$912,889 | 48,199 | −8% | Yes | |
|
|
||||||
| Aug. 28, 2026 filed Aug. 26, 2026 | Rahmer Peter See remarks | −$90,295 | 4,508 | −2% | Yes | |
|
|
||||||
| Aug. 28, 2026 filed Aug. 25, 2026 | SVF Pauling (Cayman) Ltd 10% Owner | −$116,400,000 | 6,000,000 | −22% | No | |
|
|
||||||
Showing the 5 most recent of 16 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free